FDA review timelines for new drugs extend by Q4 2026

Makary's departure signals a potential shift toward stricter oversight, delaying approvals. The new commissioner is expected to prioritize safety over speed, increasing review times for at least 3 major drug applications.

Implied probability (Yes)

70%